Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095452 | 0.93 | RCE1 (0.43) | RCE1MAPK14ACKR3CYP3A4CYP2D6 | |
| SCHEMBL3113651 | 0.88 | RCE1 (0.45) | RCE1CYP3A4CYP2D6CYP2C9NR1H4 | |
| SCHEMBL3106715 | 0.87 | GCG (0.44) | MAPK14 | |
| SCHEMBL3102072 | 0.87 | TACR1 (0.36) | RCE1MAPK14ACKR3KCNH2 | |
| SCHEMBL3095293 | 0.83 | RCE1 (0.43) | RCE1KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3098650 | 0.83 | NPC1 (0.43) | RCE1CYP3A4CYP2D6CYP2C9NR1H4 | |
| SCHEMBL3094894 | 0.82 | RCE1 (0.49) | RCE1CYP3A4CYP2D6CYP2C9NPC1 | |
| SCHEMBL3089854 | 0.82 | RCE1 (0.46) | RCE1KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3093889 | 0.81 | SMN1; SMN2 (0.35) | ACKR3KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3101341 | 0.81 | RCE1 (0.48) | RCE1CYP3A4CYP2D6CYP2C9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | RCE1 3126/4885MAPK14 1389/4885ACKR3 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.